Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

A multi-center retrospective analysis of patients with relapsed/refractory follicular lymphoma after third-line chemotherapy.

Tytuł :
A multi-center retrospective analysis of patients with relapsed/refractory follicular lymphoma after third-line chemotherapy.
Autorzy :
Fuji S; Department of Hematology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka City, Osaka, 5418567, Japan. .
Tada Y; Department of Hematology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka City, Osaka, 5418567, Japan.
Nozaki K; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Saito H; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Ozawa T; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Kida T; Department of Hematology, Toyonaka Municipal Hospital, Osaka, Japan.
Kosugi S; Department of Hematology, Toyonaka Municipal Hospital, Osaka, Japan.
Sugahara H; Department of Hematology, Sumitomo Hospital, Osaka, Japan.
Ikeda H; Department of Hematology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Hashimoto K; Department of Hematology, Kansai Rosai Hospital, Hyogo, Japan.
Karasuno T; Department of Hematology, Rinku General Medical Center, Osaka, Japan.
Ueda S; Department of Hematology, Hyogo Prefectural Nishinomiya Hospital, Hyogo, Japan.
Ishikawa J; Department of Hematology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka City, Osaka, 5418567, Japan.
Shibayama H; Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Sep; Vol. 99 (9), pp. 2133-2139. Date of Electronic Publication: 2020 Jun 12.
Typ publikacji :
Journal Article; Multicenter Study
Język :
English
Imprint Name(s) :
Publication: Berlin : Springer Verlag
Original Publication: Berlin ; New York : Springer International, c1991-
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphoma, Follicular/*diagnosis
Lymphoma, Follicular/*drug therapy
Neoplasm Recurrence, Local/*diagnosis
Neoplasm Recurrence, Local/*drug therapy
Adult ; Aged ; Cohort Studies ; Female ; Follow-Up Studies ; Humans ; Lymphoma, Follicular/mortality ; Male ; Middle Aged ; Neoplasm Recurrence, Local/mortality ; Retrospective Studies ; Survival Rate/trends
Contributed Indexing :
Keywords: Bendamustine; Follicular lymphoma; Hematopoietic stem cell transplantation; Relapse
Entry Date(s) :
Date Created: 20200614 Date Completed: 20200824 Latest Revision: 20200824
Update Code :
20201023
DOI :
10.1007/s00277-020-04126-y
PMID :
32533251
Czasopismo naukowe
The overall outcome of patients with advanced-stage follicular lymphoma (FL) has improved significantly. However, some patients still develop multiple relapsed/refractory FL (RRFL). To address the still-limited data on this population, we performed this multi-center retrospective study. We analyzed 41 patients who received third-line treatment for RRFL at 8 institutes. The median age at diagnosis was 59 years (range, 38-70). The median progression-free survival (PFS) and probability of PFS at 2 years were 1.61 years and 39.4%, respectively, after third-line chemotherapy, and 0.45 years and 19.0%, respectively, after fourth-line chemotherapy. Objective response (OR) after third-line chemotherapy was achieved in 24 patients (53.7%). Bendamustine (Ben)-based regimens were associated with a significantly higher OR rate than other regimens (77.8% vs. 40.0%, respectively, P = 0.025). The median overall survival (OS) and probability of OS at 2 years were 4.71 years and 65.9%, respectively, after third-line chemotherapy, and 1.01 year and 45.1%, respectively, after fourth-line chemotherapy. In conclusion, this study had a small sample size and retrospective design, but it was able to demonstrate poor response rate and duration in patients with multiple RRFL, particularly after fourth-line chemotherapy. The optimal treatment strategy in this population should be clarified, including possibly hematopoietic stem cell transplantation.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies